Traditional Chinese medicine companies are attacking innovative drugs, and a large number of new drugs are already on the way

In order to encourage the innovation of traditional Chinese medicine and promote the development of traditional Chinese medicine, the state has issued a series of policies and measures in recent years
.
With the support of a series of favorable policies, pharmaceutical companies are enthusiastic about the innovation of traditional Chinese medicine, and they are also becoming more and more active in the application of traditional Chinese medicine registration
.
The data shows that the number of applications for traditional Chinese medicines in 2021 will reach 1,371, setting a new high in the number of applications for traditional Chinese medicines in the past six years
.
Entering 2022, the number of registration applications for traditional Chinese medicine is still growing
.
According to incomplete statistics, in January 2022, CDE undertook a total of 128 new applications for registration of traditional Chinese medicines in terms of acceptance numbers, and in February CDE undertook a total of 92 new drug registration applications in terms of acceptance numbers
.
From January to February, CDE has undertaken a total of 220 new Chinese medicine registration applications
.
From January to February 2022, there are 13 new drug applications, 86 supplementary applications, 204 supplementary applications, 1 generic application, and 2 import applications
.
Judging from the application of Class 1 innovative drugs of traditional Chinese medicine, from January to February, a number of acceptance numbers of Class 1 innovative drugs of traditional Chinese medicine were accepted
.
Among them, in January, a total of 5 Chinese medicine category 1 innovative drug acceptance numbers were undertaken; in February, a total of 3 traditional Chinese medicine category 1 innovative drug acceptance numbers were undertaken
.
According to the industry, the research and development of Class 1 new traditional Chinese medicine drugs is an important indicator to measure the innovation ability and industry level of the traditional Chinese medicine industry
.
From the current point of view, China has entered a new stage of new drug research and development
.
The industry believes that this is mainly due to the continuous introduction of favorable policies by the state and local governments in recent years to support the innovative development of the traditional Chinese medicine industry
.
At present, the development of the traditional Chinese medicine industry has obviously become a long-term plan of the country and even all regions
.
It is expected in the industry that, due to favorable policies and the pressure of centralized procurement, pharmaceutical companies will start to strengthen the research and development of traditional Chinese medicine products, and more and more new Chinese medicine drugs will emerge in the industry one after another
.
It is understood that many companies are currently increasing investment in research and development and accelerating the innovation of traditional Chinese medicine.

.
For example, Guangzhou Baiyunshan has been continuously promoting the layout of innovative drugs in recent years, and has increased investment in research and development year by year
.
The financial report shows that in 2021, the research and development expenses of Guangzhou Baiyunshan will be 875 million yuan, a year-on-year increase of 42.
94%
.
In the new drug research and development model, Guangzhou Baiyunshan insists on "self-research + cooperation" walking on two legs
.
At present, GPHL has more than 10 Category 1 new drug projects under development, covering cardiovascular and cerebrovascular, antitumor drugs, vaccines and other fields
.
It has applied for 2 Class 1 new drugs, among which cefotaxime sodium has entered clinical phase I, and BYS10 tablets have been approved for clinical use
.
In addition to self-developed drugs, Guangzhou Pharmaceutical Baiyunshan has also developed a number of Class 1 new drugs in cooperation with leading domestic and foreign pharmaceutical companies and R&D institutions
.
Among them, the traditional Chinese medicine injection Ginkgolide B has progressed rapidly and has entered the clinical phase III, while HG030 tablets and ketamine have entered the clinical phase
I.
In addition to Guangzhou Baiyun Mountain, a large number of new traditional Chinese medicines are also on the way
.
For example, as of March 29, 2022, Warner Pharmaceuticals has obtained 21 registration approvals for traditional Chinese medicine preparations
.
The company's new class 1 traditional Chinese medicine, Ganqing Granules, has completed Phase I clinical trials and has started Phase II clinical trials
.
In addition, on February 28, Yunnan Baiyao declared a new type 1 traditional Chinese medicine drug "Quansanqi Tablets", which has also received a drug clinical trial approval notice (notice number: 2022LP00306) issued by the State Drug Administration, agreeing to carry out clinical trials Clinical trials on chest tightness and heartache caused by blood stasis
.
In general, the traditional Chinese medicine industry is ushering in a major historical development opportunity
.
In the future, with the continuous favorable policies, more innovative traditional Chinese medicine drugs with clinical evidence-based medicine value will be continuously promoted in the research and development and application, and the market space is expected to be further opened
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.